Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

CVS Pharmacies to Stock ZymaDerm™ Rapid, Painless Treatment for Molluscum Contagiosum


News provided by

Naturopathix, Inc.

Apr 08, 2014, 07:00 ET

Share this article

Share toX

Share this article

Share toX

Young girl treated with gentle, rapid acting ZymaDerm™
Young girl treated with gentle, rapid acting ZymaDerm™

Boise, ID (PRWEB) April 08, 2014 -- CVS, the largest pharmacy health care provider in the U.S., has selected ZymaDerm™, the most widely used painless treatment for molluscum contagiosum, for sale at its local stores.

“We are delighted that CVS now stocks ZymaDerm™", says Dr. Briant Burke, MD, its developer and medical director of Naturopathix, Inc. the company that markets ZymaDerm™. “If you don't see ZymaDerm™ on the shelf, just ask the pharmacist or manager for ZymaDerm™ stock number 927663. It is available without prescription.”

ZymaDerm™ is the most widely used treatment to make molluscum simply vanish, especially in children, because it is painless, inexpensive, and rapid acting.

Post this

“This makes it even easier for parents to obtain ZymaDerm™, the simple and effective all natural dab on preparation, and avoid expensive, painful, and most always ineffective treatments,” continued Dr. Burke.

ZymaDerm™ is the most widely used treatment to make molluscum simply vanish, especially in children, because it is painless, inexpensive, and rapid acting. Healing begins in 24hrs and results are often seen in just days. Since its introduction in 2003, it has enabled over 500,000 people to quickly get rid of molluscum contagiosum.

While molluscum occurs primarily in young children, it is becoming epidemic amongst adults as well. ZymaDerm™ is as effective for adults as it is for children. It may be safely used on all body areas including the face and private areas.

Many leading dermatology clinics and pediatricians have replaced or are replacing invasive and often painful treatments with this gentle, effective, natural molluscum treatment for their patients with molluscum contagiosum.

In an independent study of 346 physicians that used samples of ZymaDerm™ for their patients with molluscum contagiosum, 92% of those responding rated it as effective, while 86% stated that they were either likely or extremely likely to use ZymaDerm as their preferred treatment method for molluscum contagiosum, compared to prescription drugs, over-the-counter treatment options, or physical destruction of lesions.

ZymaDerm™ is a patented blend of powerful all natural plant-based compounds; ZymaDerm™ transforms the treatment of molluscum contagiosum from expensive and often painful procedures such as freezing, burning, or surgical removal of the lesions to simply dabbing on a pleasant aromatic blend twice a day, usually for less than a month, until the lesions completely vanish.

Rather than have patients risk painful and expensive treatments, and to encourage the use of the safe and effective topical approach, ZymaDerm™ offers a no-risk six-month money back guarantee. Dr. Burke promises, “If ZymaDerm™ does not make your child’s or your molluscum contagiosum painlessly vanish within 30 days, I’ll refund your money.”

ABOUT MOLLUSCUM CONTAGIOSUM

Molluscum contagiosum is a highly contagious skin infection caused by a virus that is a member of the poxvirus family. Molluscum symptoms include raised, unsightly, warty lesions on the skin. It is a common infection throughout the United States and occurs worldwide.

Children most frequently contract molluscum contagiosum. They catch it when they come into contact with the virus, usually on the skin of another infected child or on a wet surface infected with the virus. The lesions, which can rapidly spread, are usually seen on the face, neck, armpit, arms, and hands, but may occur anywhere on the body except the palms and soles.

ABOUT NATUROPATHIX AND ZYMADERM™

Naturopathix, Inc. develops safe, effective and inexpensive treatments for common health conditions. It utilizes state-of-the-art knowledge combined with a low technology approach to reduce the high costs of medical care for patients. It markets ZymaDerm™, the only full strength topical homeopathic for molluscum contagiosum.

The ingredients in ZymaDerm™ are based on a patented blend of powerful all natural plant-based compounds and officially included in the Homeopathic Pharmacopeia of the United States, which the FDA recognizes by law as authoritative. The potency and level of purity of the ingredients in ZymaDerm™ meet the most stringent standards of excellence. It is available in over 20,000 pharmacies including leading chain drugstores, such as CVS and Walgreens, and online merchants such as drugstore.com and amazon.com. It’s website is http://www.Naturopathix.com

Robert Schumacher, Naturopathix, Inc., http://naturopathix.com, 424-262-0606, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.